Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer

Ji-In Bang, Hai-Jeon Yoon, Bom Sahn Kim*

Department of Nuclear Medicine, Ewha Womans University School of Medicine, Seoul, South Korea

* kbomsahn@ewha.ac.kr

Abstract

Background

The aim of this study was to investigate the metabolism of the spleen, bone marrow (BM), and liver from preoperative F-18 FDG PET/CT scans for the prediction of recurrence in breast cancer.

Methods

We retrospectively included 153 patients diagnosed with invasive ductal carcinoma (IDC) of the breast who underwent preoperative F-18 FDG PET/CT scan and a curative operation. The mean standardized uptake value (SUV\text{mean}) of the spleen, liver, and BM and maximum SUV (SUV\text{max}) of primary tumors were measured. The relationships between spleen, BM, and liver metabolism and clinicopathologic parameters were evaluated, and possible prognostic parameters predicting recurrence were assessed using disease-free survival (DFS).

Results

Spleen SUV\text{mean} was significantly correlated with primary tumor SUV\text{max}, pathologic T (pT) stage, and histologic grade of primary tumor. BM SUV\text{mean} also showed a positive correlation with primary tumor SUV\text{max}. Spleen SUV\text{mean} were significantly associated with recurrence from binary logistic regression analysis ($P = 0.004$). Spleen, BM, liver, and primary tumor SUVs were all significant prognostic factors for DFS in univariate Cox regression analysis (all $P < 0.024$). Among all PET parameters analyzed, spleen SUV\text{mean} $\geq$ 2.21 ($P = 0.032$) was in the multivariable analysis the powerful poor prognostic factor predicting DFS that was independent of other clinicopathological features like T stage ($pT > 2$; $P = 0.009$) and estrogen receptor (ER) status (ER negativity; $P = 0.001$).

Conclusion

Splenic metabolism together with pT stage and ER status was an independent prognostic factor for predicting recurrence in breast cancer. Metabolic activity of reticuloendothelial...
Introduction

In recent years, the systemic inflammatory response to cancer has received growing interest as an important factor in cancer development and prognosis [1–4]. Consistent evidence indicates that a systemic inflammatory response in cancer is related to the prognosis of various cancers [5]. Therefore, it is anticipated that assessing the systemic inflammatory response in cancer patients could be useful as a stratification marker for oncologic clinical practice. Biomarkers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein (CRP), and cytokines have been suggested as measurable parameters of systemic inflammation and prognostic predictors in various cancers [3, 5, 6].

F-18 fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) has been widely used in oncology to evaluate the metabolism of tumors. There have been attempts to measure the systemic inflammatory response from F-18 FDG PET/CT. As F-18 FDG uptake indicates glycolytic activity, not only in tumorous conditions, but also under inflammation, the systemic inflammatory response can be detected and assessed through F-18 FDG PET/CT images. Because the metabolism of bone marrow (BM) is known to correlate with hematologic parameters [7, 8], there have been several reports that F-18 FDG uptake of BM could be useful for assessing the systemic inflammatory response as a predictor of prognosis in various cancers including lung cancer [9], stomach cancer [10], and colorectal cancer [11]. As components of the reticuloendothelial system (RES), spleen and liver also have been considered integral parts of the systemic inflammatory response in cancer [12]. Activation of RES organs can be measured by metabolic activity using F-18 FDG PET/CT [13]. Metabolic activity of the spleen is known to be an independent prognostic factor in lung cancer and cholangiocarcinoma [14, 15]. Also, previous study from stomach cancer patients showed that splenic metabolism might have a predictive role in prognosis [16]. Therefore, the metabolic activity of BM and spleen on F-18 FDG PET/CT could be a promising prognostic indicator in various type of cancer patients.

In breast cancer, the pretreatment values of NLR and PLR are known predictors of mortality [17–20]. Recently, metabolism of RES organs on F-18 FDG PET/CT showed significant correlation with clinicopathological features in breast cancer patients [21]. However, the clinical prognostic significance of the F-18 FDG uptake of spleen, BM, or liver has not been assessed in patients with breast cancer. In the present study, we investigated the relationships between F-18 FDG uptake of the spleen, BM, and liver on F-18 FDG PET/CT with clinicopathological parameters and assessed the possible prognostic value of the F-18 FDG parameters in predicting disease-free survival (DFS) in patients with breast cancer.

Materials and methods

All procedures were in accordance with the principles of the 1975 Declaration of Helsinki (2013 revision). Study design and exemption from informed consent were approved by the Institutional Review Board of Mokdong Hospital of Ewha Womans University (No.2018-04-036).
Patients

We retrospectively reviewed patients who were histopathologically diagnosed with invasive ductal carcinoma (IDC) of the breast and underwent a preoperative F-18 FDG PET/CT scan for initial staging procedure between November 2010 and April 2014 in our medical center. Patients who underwent neoadjuvant chemotherapy before the operation due to clinically stage of T4 (cT4) or over N2 (cN2) were not included. In addition, in case of below cT3 or cN1, patients who underwent neoadjuvant chemotherapy for purpose of breast-preservation were not included. Among the eligible patients, we excluded those who (i) had tumors <1 cm in size to minimize a partial-volume averaging effect in analysis of F-18 FDG PET/CT images, (ii) had a previous history of any other malignancy or other malignancy that developed during follow-up, (iii) were lost to follow-up before 6 months after surgery without any event, (iv) refused to receive adjuvant therapy after surgery, (v) had any liver disease including chronic viral infection (hepatitis B or C) or abnormal liver function test (LFT) results in a preoperative assessment, and (vi) had history of recent administration of medication such as granulocyte-colony stimulating factor (G-CSF). We also reviewed the electronic medical record to reveal any clinical symptom or sign other than breast cancer at the time of preoperative work-up for possible other underlying disease.

Clinicopathological and survival data

Clinicopathological data that were considered potentially relevant for prognosis were collected from electronic medical records. Data included age at initial diagnosis, sex, menopausal status, body mass index (BMI) defined as the ratio of body weight in kilograms to the square of height in meters, and blood tests results as preoperative work-up including whole blood cell count, platelets, and hemoglobin (Hb). NLR and PLR were calculated using preoperative blood cell count results. Pathologic data included pathologic stages (pT, pN) based on the 7th American Joint Committee on Cancer staging system [22], pathologic tumor diameter, surgical margin involvement, Black’s nuclear grade, and Bloom-Richardson’s histologic grade. Immunohistochemical results evaluating the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 were also collected. ER and PR positivity statuses were defined using both scoring parameters of the percentage of positive cells (from 0 to 5) and staining intensity (from 0 to 3). A total score of 0–2 was considered negative for each hormone, and 3–8 was considered positive. HER2 was defined as negative when the immunohistochemistry results were negative or 1+ and positive when the results were 3+. When the results were 2+, the positivity of HER2 was defined according to the results of fluorescence in situ hybridization (FISH). For the marker Ki67, overexpression was defined as present in more than 14% of the tumor cells.

LFT results including liver transaminase (aspartate aminotransferase, AST, and alanine aminotransferase, ALT), total bilirubin, and serologic evaluation for hepatitis B and C as preoperative work-up were included.

After curative surgery, adjuvant therapy was performed according to pathologic staging and clinical condition of the patients. Regular clinical follow-up was conducted with physical examination, blood test, ultrasonography, chest X-ray, and bone scan every 3 to 6 months in the first 2 years and every 6 to 12 months after that. When recurrence was suspected, additional procedures for pathological confirmation or imaging work-up were performed. For survival analysis, DFS was defined as the time between the date of operation and the date that any recurrence was first identified.
Acquisition of F-18 FDG PET/CT

Acquisition of F-18 FDG PET/CT was done as described in detail previously [23]. All patients fasted for at least 6 h before the F-18 FDG PET/CT scans. Blood glucose level was measured and was required to be less than 140 mg/dL before intravenous injection of 5.18 MBq/kg of F-18 FDG. A CT scan was performed at 120 kVp without contrast enhancement for attenuation correction and anatomical information. A PET scan was obtained from the skull base to the upper thigh, using a Siemens Biograph mCT with 128-slice CT (Siemens Medical Solutions, Erlangen, Germany) at 1 h (mean 60.7 min, range 51–79 min) after FDG injection. The spatial resolution at the center of the PET was 2.0 mm full width at half maximum (FWHM) in the transaxial direction and 2.0 mm FWHM in the axial direction. Three-dimensional emission was used for the acquisition parameters for PET images, and it required a 2 min scan per bed position for 5–7 positions. PET images were reconstructed to 200 × 200 matrices and 3.4 mm × 3.4 mm pixel sizes with a 3.0-mm slice thickness using a three-dimensional OSEM iterative algorithm (2 iterations and 21 subsets) with time of flight and point spread functions. The patients were in a supine position and allowed to breathe normally during PET/CT image acquisition.

Analysis of F-18 FDG PET/CT imaging

All PET/CT data were analyzed using a commercially available system (Syngo.via; Siemens Medical Solutions, Erlangen, Germany). The maximal standardized uptake value (SUV_max) corrected for the individual patient body weight for primary breast cancer lesion (primary tumor SUV_max), and the mean SUVs (SUV_mean) of spleen, liver, and BM were measured.

Regions of interest (ROI) were placed over the primary tumor using the automated delineation features in commercial software described in above. For spleen SUV_mean, a spherical volume of interest (VOI) was drawn manually on the center of the spleen, which showed the largest anterior-posterior diameter on the axial image. To validate method of spleen SUV measurement, the inter-rater variability was assessed. Two nuclear medicine physicians who were strictly blinded to the patient’s clinical information measured the spleen SUVs. The metabolism of BM was measured using a method reported previously [9, 11, 24, 25]. A spherical VOI was drawn over the vertebral body of T10-T12 spines and L3-5 spines, and the SUV_mean was measured using the 75% cutoff value of the SUV_max. Compromised spine, such as compression fracture, degeneration, or postoperative change, was omitted from BM metabolism measurement. The mean value of SUV_mean of BM was defined as BM SUV_mean. For measuring the metabolism of the liver (liver SUV_mean), a spherical VOI was automatically placed on the right of the liver using a fixed size (3 cm diameter). All automatically drawn reference VOIs were reviewed and manually redrawn if the CT scan quality was compromised or the liver was displaced by other lesions.

Statistical analysis

First, intraclass correlation coefficient was used to assess the inter-rater variability in spleen SUV measurements. To evaluate the relationships between metabolism of spleen, BM, liver and clinicopathological parameters, Spearman’s rank correlation analyses were employed. Clinicopathological and PET parameters were analyzed using binary logistic regression for possible prediction of recurrence. Survival analysis was performed using clinicopathological and PET parameters as covariates and tumor recurrence as endpoints. DFS was calculated using the Kaplan-Meier method. Univariate Cox regression analysis was performed for each parameter and variable, and those with a P value less than 0.05 were included in the multivariable analysis. For multivariable Cox regression, the forward conditional method (entry
threshold \( P < 0.05 \); removal threshold \( P > 0.1 \) was applied. For continuous variables, optimal cutoff points for parameters were determined by finding the point with the most significant (log-rank test) split of DFS, using web-based R software engineered and designed by Budczies et al. [26] (http://molpath.charite.de/cutoff/). Receiver operating characteristic (ROC) curves were generated, and area of under the ROC (AUC) for each optimal cutoff point were calculated to assess the predictive performance of recurrence. All statistical analyses were performed using a commercial statistical software package (SPSS Ver. 19.0; SPSS Inc., Chicago, IL), and two-sided \( P \)-values \(< 0.05\) were considered statistically significant. For ROC analyses, GraphPad software (San Diego, CA) was used.

**Results**

**Patient characteristics**

We initially enrolled 226 female patients who fulfilled the inclusion criteria. Eleven patients (over cN2, \( n = 8 \); for breast-preservation, \( n = 3 \)) were excluded due to neoadjuvant therapy. A total of 62 patients were excluded from final analysis due to tumor size \(< 1\) cm (\( n = 29 \)), short follow-up period (\( n = 10 \)), underlying malignancy other than breast cancer (\( n = 12 \)), refusal of adjuvant therapy (\( n = 5 \)), and underlying liver disease or abnormal LFT results (\( n = 6 \)). The final analysis included 153 patients. Table 1 summarizes the demographics and tumor characteristics of the 153 enrolled patients. None of those enrolled patients received the G-CSF at the time of preoperative work-up or revealed any acute clinical symptom or sign other than breast cancer.

Among the 153 patients, 19 (12.4\%) had tumor recurrence. The mean clinical follow-up duration of the patients was 79.2 months (95\% CI 75.4–83.1 months, range 8–88 months). Sites of tumor recurrence were locoregional sites (nine patients), lymph nodes (three patients), bone (two patients), brain (one patient), lung (two patients), liver (one patient), and multiple organs (one patient).

**Inter-rater variability in spleen SUV measurement**

The intraclass correlation coefficient was 0.954, indicating the high reproducibility of measuring the spleen SUV manually via spherical VOI on the center of spleen, which showed the largest anterior-posterior diameter on the axial image.

**Relationships between metabolism of BM, spleen, and liver and clinicopathologic parameters**

Correlation analysis between the metabolism of spleen, BM, and liver and tumor-related parameters revealed that spleen SUV\(_{\text{mean}}\) was correlated significantly and positively with primary tumor SUV\(_{\text{max}}\) (\( \rho = 0.187, P = 0.021, \) Fig 1A), pT stage (pT1 vs T2+3; \( \rho = 0.165, P = 0.042 \)), and histologic grade (grade 1 vs grade 2+3; \( \rho = 0.212, P = 0.008 \)). BM SUV\(_{\text{mean}}\) also showed a positive correlation with primary tumor SUV\(_{\text{max}}\) (\( \rho = 0.323, P < 0.001, \) Fig 1B).

Relationships between the metabolism of the spleen, BM, and liver and clinical parameters showed that the spleen, BM, and liver SUV\(_{\text{mean}}\) each had a positive correlation with BMI (\( \rho = 0.551, P < 0.001 \) for spleen SUV\(_{\text{mean}}\); \( \rho = 0.224, P = 0.005 \) for BM SUV\(_{\text{mean}}\); \( \rho = 0.434, P < 0.001 \) for liver SUV\(_{\text{mean}}\)). There was a significant negative correlation between BM SUV\(_{\text{mean}}\) and Hb (\( \rho = -0.202, P = 0.012 \)). However, spleen, BM, or liver SUV\(_{\text{mean}}\) was not correlated with any clinical parameters including WBC, NLR, and PLR.
Table 1. Characteristics of the 153 enrolled patients.

| Characteristics                      | Number | %   |
|--------------------------------------|--------|-----|
| **Sex**                              |        |     |
| Female, n (%)                        | 153    | 100 |
| **Age (years) at initial diagnosis, mean±SD (range)** | 49.5±9.6 (30–79) | |
| **Menopausal status**                |        |     |
| Premenopausal                        | 105    | 68.6|
| Postmenopausal                       | 48     | 31.4|
| **Operation**                        |        |     |
| Breast-conserving surgery            | 130    | 85.0|
| Mastectomy                           | 23     | 15.0|
| **pT stage**                         |        |     |
| T1                                   | 90     | 58.8|
| T2                                   | 61     | 39.9|
| T3                                   | 2      | 1.3 |
| **pN stage**                         |        |     |
| N0                                   | 107    | 69.9|
| N1                                   | 36     | 23.5|
| N2                                   | 9      | 5.9 |
| N3                                   | 1      | 0.7 |
| **ER status**                        |        |     |
| Positive                             | 104    | 68.0|
| Negative                             | 49     | 32.0|
| **PR status**                        |        |     |
| Positive                             | 105    | 68.6|
| Negative                             | 48     | 31.4|
| **HER2 status**                      |        |     |
| Positive                             | 40     | 26.1|
| Negative                             | 113    | 73.9|
| **Ki67 index status**                |        |     |
| <14%                                 | 53     | 36.3|
| ≥14%                                 | 93     | 63.7|
| **Resection margin involvement**     |        |     |
| Negative                             | 150    | 98.0|
| Positive                             | 3      | 2.0 |
| **Nuclear grade**                    |        |     |
| Grade 1                              | 6      | 3.9 |
| Grade 2                              | 87     | 56.9|
| Grade 3                              | 60     | 39.2|
| **Histologic grade**                 |        |     |
| Grade 1                              | 28     | 18.3|
| Grade 2                              | 68     | 44.4|
| Grade 3                              | 57     | 37.3|
| **Pathologic Stage**                 |        |     |
| I                                    | 74     | 48.4|
| II                                   | 68     | 44.4|
| III                                  | 11     | 7.2 |
| **Adjuvant Treatment**               |        |     |
| CTx+RTx+HTx                          | 111    | 72.5|

(Continued)
**ROC curves analysis**

The AUCs were 0.76, 0.67, 0.57 and 0.61 for primary tumor SUVmax, spleen, BM and liver SUVmean, respectively (Fig 2). Each optimal cutoff point determined by finding the point with the most significant (log-rank test) split of DFS were 11.27 (sensitivity 47.4%, specificity 90.3%), 2.21 (sensitivity 31.6%, specificity 94.8%), 2.625 (sensitivity 21.1%, specificity 94.8%), and 2.935 (sensitivity 21.1%, specificity 94%) for primary tumor SUVmax, spleen, BM and liver SUVmean, respectively.

**Recurrence and clinicopathologic, PET parameters**

Binary logistic regression was performed to evaluate the possible clinicopathological and PET parameters for the prediction of recurrence. For clinical parameters, only BMI was significantly associated with recurrence. Pathological parameters including pT stage, lymph node metastasis, ER/PR status, tumor involvement of resection margin, nuclear grade, and histologic grade were significantly associated with recurrence. Among PET parameters, primary tumor SUVmax and spleen SUVmean were significantly associated with recurrence. Table 2 summarizes the results of binary logistic regression associated with recurrence.

**DFS analysis**

Univariate Cox regression analysis of DFS was performed to evaluate the prognostic potential of clinicopathological and PET parameters (Table 3). For clinical parameters, BMI and WBC were significantly associated with DFS ($P<0.05$). For pathologic parameters, pT stage, lymph node metastasis, ER/PR/HER2 status, tumor involvement of resection margin, nuclear grade, and histologic grade were significantly associated with DFS ($P<0.05$). For PET parameters, spleen SUVmean, BM SUVmean, liver SUVmean, and primary tumor SUVmax were significant prognostic factors for DFS ($P<0.05$, Fig 3).

Of the variables, those with a $P$-value less than 0.05 in univariate Cox regression analysis were selected for multivariable analysis. Among these variables, BM and liver SUVmean were excluded, and only spleen SUVmean was included in the multivariable analysis due to possible biological correlation among the three organs as responders to systemic inflammatory change.
Fig 1. Scatter plot showing the relationships between primary tumor standardized uptake value (SUV)$_{\text{max}}$ and (A) spleen SUV$_{\text{mean}}$ and (B) bone marrow (BM) SUV$_{\text{mean}}$.

https://doi.org/10.1371/journal.pone.0208861.g001
Multivariable analysis revealed that spleen SUV_{mean} was a factor predicting DFS independent of pT stage and ER status ($P = 0.032$, Table 4).

Discussion

In this retrospective study, we found that spleen and BM metabolism showed a significant correlation with the tumor characteristics of breast cancer. Moreover, splenic metabolism from a pretreatment F-18 FDG PET/CT scan could potentially be used as a prognostic indicator for recurrence in breast cancer patients.

Spleen and BM SUVs were correlated with primary tumor SUV_{max}, which was consistent with the findings of previous studies from breast, stomach or colorectal cancer [10, 11, 16, 21]. Primary tumor SUV_{max} is known as a prognostic factor of breast cancer [23, 27]. A recent study also revealed that inflammatory response in tumor-adjacent parenchyma could be associated with poor prognosis in breast cancer [28]. In particular, tumor necrosis factor (TNF) signaling pathway was associated with paratumoral inflammatory change in breast cancer, and this inflammatory process could be detected by imaging [28]. Cytokines such as TNF are well known pro-inflammatory cytokine associated with tumor proliferation and invasion [29]. F-18 FDG is a nonspecific tracer reflecting not only tumoral metabolism, but also an inflammatory process. As primary tumors show more aggressiveness, a more severe systemic inflammatory response could be triggered and could be detected by splenic and BM metabolism on F-18 FDG PET/CT. Although spleen, BM, and liver metabolisms were all significant predictors of recurrence in our patients, splenic metabolism could be the most powerful prognostic predictor among the three organs. In our study, due to the possible biological correlation between
|                                | Non-rec (n or mean±SD) | Recur (n or mean±SD) | P value | Odds ratio | 95% CI      |
|--------------------------------|------------------------|----------------------|---------|------------|-------------|
| Age (years) at diagnosis       | 49.5±9.9               | 49.0±7.3             | 0.806   | 0.994      | 0.944–1.046 |
| BMI                            | 23.2±3.2               | 25.2±4.2             | 0.014   | 1.181      | 1.034–1.349 |
| Menopausal status              |                        |                      |         |            |             |
| Premenopausal                  | 94                     | 11                   | -       | -          | -           |
| Postmenopausal                 | 40                     | 8                    | 0.289   | 1.638      | 0.659–4.071 |
| WBC (x 10¹² cells/L)           | 5.97±1.47              | 6.60±1.54            | 0.088   | 1.315      | 0.960–1.802 |
| Platelet (x 10¹² cells/L)      | 262.1±62.8             | 270.7±58.0           | 0.573   | 1.002      | 0.995–1.010 |
| Hemoglobin (g/dL)              | 13.2±1.3               | 12.9±1.5             | 0.321   | 0.850      | 0.616–1.172 |
| NLR                            | 1.89±0.91              | 1.71±0.53            | 0.383   | 0.741      | 0.379–1.452 |
| PLR                            | 141.2±50.5             | 124.7±34.7           | 0.161   | 0.991      | 0.978–1.004 |
| pT stage‡                      |                        |                      |         |            |             |
| T1                             | 89                     | 1                    | -       | -          | -           |
| T2 + T3                        | 45                     | 18                   | 0.001   | 35.600     | 4.604–272.251 |
| Lymph node metastasis          |                        |                      |         |            |             |
| Absence                        | 99                     | 8                    | -       | -          | -           |
| Presence                       | 35                     | 11                   | 0.007   | 3.889      | 1.447–10.456 |
| ER status                      |                        |                      |         |            |             |
| Positive                       | 33                     | 16                   | -       | -          | -           |
| Negative                       | 101                    | 3                    | <0.001  | 16.323     | 4.474–59.550 |
| PR status                      |                        |                      |         |            |             |
| Positive                       | 34                     | 14                   | -       | -          | -           |
| Negative                       | 100                    | 5                    | <0.001  | 8.235      | 2.761–24.561 |
| HER2 status                    |                        |                      |         |            |             |
| Negative                       | 102                    | 11                   | -       | -          | -           |
| Positive                       | 32                     | 8                    | 0.112   | 2.093      | 0.842–5.205 |
| Ki67 index status†             |                        |                      |         |            |             |
| <14%                           | 50                     | 3                    | -       | -          | -           |
| ≥ 14%                          | 77                     | 16                   | 0.058   | 3.463      | 0.960–12.499 |
| Tumor involvement of resection margin |                    |                      |         |            |             |
| Negative                       | 133                    | 17                   | -       | -          | -           |
| Positive                       | 1                      | 2                    | 0.028   | 15.647     | 1.346–181.862 |
| Nuclear grade                  |                        |                      |         |            |             |
| Grade 1+2                      | 89                     | 4                    | -       | -          | -           |
| Grade 3                        | 45                     | 15                   | 0.001   | 7.417      | 2.326–23.652 |
| Histologic grade               |                        |                      |         |            |             |
| Grade 1+2                      | 92                     | 4                    | -       | -          | -           |
| Grade 3                        | 42                     | 15                   | <0.001  | 8.214      | 2.571–26.249 |
| Primary tumor SUVmax           | 6.0±4.0                | 10.9±6.1             | <0.001  | 1.210      | 1.098–1.333 |
| Spleen SUVmean                 | 1.90±0.21              | 2.62±0.31            | 0.004   | 25.321     | 2.807–228.393 |
| BM SUVmean                     | 2.06±0.32              | 2.16±0.42            | 0.212   | 2.400      | 0.607–9.487 |
| Liver SUVmean                  | 2.49±0.26              | 2.62±0.31            | 0.062   | 5.781      | 0.916–36.481 |

BMI: body mass index, WBC: whole blood cell counts, NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor 2, BM: bone marrow

† Pathologic staging according to the 7th AJCC

‡ Ki67 value for 146 patients

https://doi.org/10.1371/journal.pone.0208861.t002
the metabolism of the three organs, multivariable analyses only included the spleen SUV mean because splenic metabolism showed the most powerful predictive ability among the three organs in binary logistic regression and univariate analyses.

RES, formally called mononuclear phagocytic system (MPS) is a fundamental immune response mainly composed with phagocytes. The spleen, liver and BM are organs with high RES activity [30]. Previous studies revealed the measurement of metabolic activity of those organs on F-18 FDG PET/CT could be macroscopic approach to evaluate the assessment of immune activity of RES. Several studies have linked splenic metabolism with activation of a

| Table 3. Univariate Cox regression analysis of disease free survival. |
|------------------|--------|-------|-------|
| Variable          | P value | HR    | 95% CI |
| Age at diagnosis  | 0.810  | 0.994 | 0.948–1.042 |
| BMI (<25.0 vs. >25.0) | 0.020  | 2.78  | 1.130–6.840 |
| Menopausal status (pre vs. post) | 0.289  | 1.638 | 0.659–4.071 |
| WBC (<6.39 x 10^12 cells/L vs. >6.39 x 10^12 cells/L) | 0.022  | 2.84  | 1.120–7.210 |
| Platelet (<348 x 10^12 cells/L vs. >348 x 10^12 cells/L) | 0.240  | 2.05  | 0.600–7.030 |
| Hb (<14.5 g/dL vs. >14.5 g/dL) | 0.288  | 0.041 | 0.000–15.070 |
| NLR (<2.505 vs. >2.505) | 0.256  | 0.039 | 0.000–10.474 |
| PLR (<140.7 vs. >140.7) | 0.051  | 0.293 | 0.085–1.005 |
| pT stage† (T1 vs. T2+T3) | 0.001  | 30.100 | 4.016–225.582 |
| Lymph node metastasis (absence vs. presence) | 0.007  | 3.523  | 1.416–8.761 |
| ER status (positive vs. negative) | <0.001  | 13.754 | 4.003–47.256 |
| PR status (positive vs. negative) | <0.001  | 7.487 | 2.694–20.804 |
| HER2 status (positive vs. negative) | 0.112  | 0.478 | 0.192–1.188 |
| Ki67 index status (<14% vs. >14%)‡ | 0.051  | 3.408 | 0.993–11.700 |
| Tumor involvement of resection margin (negative vs. positive) | 0.003  | 9.057 | 2.080–39.430 |
| Nuclear grade (Grade 1+2 vs. 3) | 0.001  | 6.634 | 2.200–20.001 |
| Histologic grade (Grade 1+2 vs. 3) | <0.001  | 7.290 | 2.418–21.982 |
| Primary tumor SUV_{max} (<11.27 vs. ≥11.27) | <0.001  | 6.83 | 2.770–16.850 |
| Spleen SUV_{mean} (<2.21 vs. ≥2.21) | <0.001  | 6.29 | 2.680–16.610 |
| BM SUV_{mean} (<2.625 vs. ≥2.625) | 0.010  | 3.87 | 1.280–11.690 |
| Liver SUV_{mean} (<2.935 vs. ≥2.935) | 0.024  | 3.33 | 1.100–10.030 |

BMI body mass index, WBC white blood cell count, Hb hemoglobin, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, BM bone marrow

‡Ki67 value for 146 patients

†Pathologic staging according to the 7th AJCC

https://doi.org/10.1371/journal.pone.0208861.t003
systemic inflammatory response in patients with inflammatory [13, 31] and cardiovascular diseases [32, 33]. The metabolism of the spleen has also received attention as a prognostic predictor because it is a reflector of the systemic inflammatory response to cancer [14–16]. In addition, our results indicate that splenic metabolism as a component of RES might be useful as a possible stratification parameter of F-18 FDG PET/CT in breast cancer patients.

Although the metabolisms of the spleen, BM, and liver were significant parameters in prediction of recurrence, hematologic parameters other than Hb did not correlate with metabolism of these organs. A possible explanation could be failure of NLR or PLR in predicting the recurrence of breast cancer patients in our study contrary to previous studies [17–20]. There have been controversies on the association between PLR and prognosis of breast cancer patients, possibly due to different study groups and cutoff values [18–20]. We included patients who underwent curative surgical resection without neoadjuvant therapy; therefore, the included study group might be at an earlier stage than patient groups reported previously. Furthermore, a possible explanation may be that the metabolism of the spleen, BM, or liver on F-18 FDG PET/CT could precede a change in peripheral blood cell counts.

Another consideration was the negative correlation between the metabolism of BM and Hb level. The metabolism of BM on F-18 FDG PET/CT might represent an aggregate of the complex processes of hematopoiesis, which occur not only from a systemic inflammatory response, but also in response to anemia. In this context, measuring the metabolism of the spleen could

Table 4. Multivariate Cox regression analysis of disease free survival.

| Variable (description)                              | β     | Hazard ratio | 95% CI       | P value |
|----------------------------------------------------|-------|--------------|--------------|---------|
| pT stage (T1 vs. T2+T3)                            | 2.740 | 15.482       | 1.998–119.958| 0.009   |
| ER status (Positive vs. negative)                  | 2.155 | 8.629        | 2.489–29.912 | 0.001   |
| Spleen SUVmean (< 2.21 vs. ≥2.21)                 | 1.080 | 2.944        | 1.098–7.896  | 0.032   |

https://doi.org/10.1371/journal.pone.0208861.t004
be more straightforward than the metabolism of BM in representing the systemic inflammatory response. In addition, although compromised spines due to skeletal problems were eliminated from the measurement, measuring the BM could be technically affected by the metabolic activity of bony cortex of vertebra. Although the methodology of measuring BM metabolism was established through several studies, assessing the metabolism of the spleen might be more feasible than the metabolism of BM on F-18 FDG PET/CT scans [9, 11, 24, 25]. Taken together, these findings indicate that splenic metabolism could represent a systemic inflammatory response to cancer and be used as a possible prognostic predictor in breast cancers.

A limitation of this study was the relatively small number of enrolled patients and the retrospective design from a single center. Due to a few recurrence events, there was a limitation in designing the models of multivariable analysis. A large number of patients from multiple centers with further long-term follow-up might be needed to cross-validate our findings. In our study, enrolled patients were mainly early breast cancer, therefore, assessment of advanced breast cancer should be needed. Furthermore, study on stratification of RES metabolism among staging and molecular subtypes of breast cancer might lead to the profound understanding to RES metabolism. Moreover, other biomarkers, such as CRP, could not be assessed in this study because they were not included in routine preoperative work-up. It might be helpful to include biomarkers representing the systemic inflammatory response to differentiate the stratification of prognosis in cancer patients as a preoperative assessment.

Interestingly, the metabolisms of spleen, BM, and liver were all significantly correlated with BMI. Obesity induces a chronic low-grade systemic inflammation and is known as a risk factor of various cancers including breast cancer [34, 35]. Even though the metabolism of the liver could be affected by various factors [36–38], there has been indirect evidence of the relationship between metabolism of the liver and obesity [39]. In our study, we excluded patients who had liver disease or abnormal LFT to avoid a possible confounding effect on liver metabolism. Therefore, our results might be indirect evidence of the metabolism of the spleen, BM, and liver on F-18 FDG PET as possible representations of systemic inflammation from obesity.

Although a direct linkage between systemic inflammatory response and cancer prognosis has not been shown, and the metabolism of RES, measured from the spleen, BM, or liver on F-18 FDG PET/CT could be a mixture of complex systemic responses to cancer, our study indicates that the metabolism of spleen, BM, and liver on F-18 FDG PET/CT could be used as a prognostic predictor of breast cancer.

**Conclusion**

Metabolism of the spleen, BM, and liver on F-18 FDG PET/CT might be prognostic predictors in breast cancer patients. In particular, the splenic metabolism from preoperative F-18 FDG PET/CT might be useful for predicting recurrence in breast cancer. Although further evidence is needed to connect the metabolism of the spleen, BM, or liver to the systemic inflammatory response and to cancer prognosis, the metabolism of the spleen, BM, and liver on F-18 FDG PET/CT could be used as a prognostic predictor of breast cancer. Splenic metabolism on preoperative F-18 FDG PET/CT might be a meritorious imaging factor for discriminating patients with IDC that require adjunctive therapy to prevent recurrence.

**Supporting information**

S1 File. Supporting data set.

(PDF)
Acknowledgments
This research was supported by the NRF funded by the Ministry of education (grant number, NRF-2018R1D1A1B07045321) and by Ewha Womans University (2018-0722-001-1 and 2018-0768-001-1). The funders had no role in study design, data collection and analysis, or preparation of the manuscript.

Author Contributions
Conceptualization: Hai-Jeon Yoon, Bom Sahn Kim.
Data curation: Ji-In Bang.
Formal analysis: Ji-In Bang.
Funding acquisition: Bom Sahn Kim.
Investigation: Ji-In Bang.
Methodology: Hai-Jeon Yoon.
Writing – original draft: Ji-In Bang.
Writing – review & editing: Ji-In Bang, Hai-Jeon Yoon, Bom Sahn Kim.

References
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646–74. https://doi.org/10.1016/j.cell.2011.02.013 PMID: 21376230
2. Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulios AK, Horgan PG, et al. The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer. 2010; 103:870–6. https://doi.org/10.1038/sj.bjc.660555 PMID: 20717110
3. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncology. 2010; 6:149–63. https://doi.org/10.2217/fon.09.136 PMID: 20021215
4. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014; 110:1409–12. https://doi.org/10.1038/bjc.2014.90 PMID: 24548867
5. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013; 88:218–30. https://doi.org/10.1016/j.critrevonc.2013.03.010 PMID: 23602134
6. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39:534–40. https://doi.org/10.1016/j.ctrv.2012.08.003 PMID: 22995477
7. Inoue K, Goto R, Okada K, Kinomura S, Fukuda H. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med. 2009; 23:643–9. https://doi.org/10.1007/s12149-009-0286-9 PMID: 19629627
8. Murata Y, Kubota K, Yukihiro M, Ito K, Watanabe H, Shibuya H. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol. 2006; 33:999–1004. https://doi.org/10.1016/j.nucmedbio.2006.09.006 PMID: 17127173
9. Lee JW, Choi JS, Lyu J, Lee SM. Prognostic significance of 18F-fluorodeoxyglucose uptake of bone marrow measured on positron emission tomography in patients with small cell lung cancer. Lung Cancer. 2010; 118:41–7. https://doi.org/10.1016/j.lungcan.2010.01.020 PMID: 20972001
10. Lee JW, Lee MS, Chung IK, Son MW, Cho YS, Lee SM. Clinical implication of FDG uptake of bone marrow on PET/CT in gastric cancer patients with surgical resection. World J Gastroenterol. 2017; 23:2385–95. https://doi.org/10.3748/wjg.v23.i13.2385 PMID: 28428718
11. Lee JW, Baek M-J, Ahn TS, Lee SM. Fluorine-18-fluorodeoxyglucose uptake of bone marrow on PET/CT can predict prognosis in patients with colorectal cancer after curative surgical resection. European Journal of Gastroenterology & Hepatology. 2018; 30:187–94.
12. Bronte V, Pittet Mikael J. The Spleen in Local and Systemic Regulation of Immunity. Immunity. 2013; 39:806–18. https://doi.org/10.1016/j.immuni.2013.01.010 PMID: 24238398
13. Ahn SS, Hwang SH, Jung SM, Lee SW, Park YB, Yun M, et al. Evaluation of Spleen Glucose Metabolism Using (18)F-FDG PET/CT in Patients with Febrile Autoimmune Disease. J Nucl Med. 2017; 58:507–13. https://doi.org/10.2967/jnumed.116.180729 PMID: 27688472

14. Pak K, Kim SJ, Kim IJ, Kim DU, Kim K, Kim H, et al. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma. Nuklearmedizin. 2014; 53:26–31. https://doi.org/10.3413/Nukmed-0566-13-03 PMID: 24305850

15. Bural GG, Torigian DA, Chen W, Houseni M, Basu S, Alavi A. Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response. Heil J Nucl Med. 2010; 13:23–5. PMID: 20411166

16. Yoon HJ, Kim BS, Moon CM, Yoo J, Lee KE, Kim Y. Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer. PLoS One. 2018; 13:e0196110. https://doi.org/10.1371/journal.pone.0196110 PMID: 29698422

17. Ethier J-L, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Research: BCR. 2017; 19:2. https://doi.org/10.1186/s13058-016-0794-1 PMID: 28057046

18. Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015; 113:150–8. https://doi.org/10.1038/bjc.2015.183 PMID: 26022929

19. Krenn-Pilko S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014; 110:2524–30. https://doi.org/10.1038/bjc.2014.163 PMID: 24675383

20. Zhu Y, Si W, Sun Q, Qin B, Zhao W, Yang J. Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer. Oncotarget. 2017; 8:1023–30. https://doi.org/10.18632/oncotarget.13714 PMID: 27906679

21. Şahin E, Elboğa U. Relationship between reticuloendothelial systems’ FDG uptake level and clinico-pathological features in patient with invasive ductal breast cancer. La radiologia medica. 2017; 122:785–92. https://doi.org/10.1007/s11547-017-0779-x PMID: 28597239

22. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–4. https://doi.org/10.1245/s10434-010-0985-4 PMID: 20180029

23. Yoo J, Yoon H-J, Kim BS. Prognostic value of primary tumor SUV max on F-18 FDG PET/CT compared with semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer. Annals of nuclear medicine. 2017; 31:19–28. https://doi.org/10.1007/s12149-016-1127-2 PMID: 27645144

24. Prevost S, Boucher L, Larivee P, Boileau R, Benard F. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer. J Nucl Med. 2006; 47:559–65. PMID: 16595487

25. Lee JW, Na JO, Kang DY, Lee SY, Lee SM. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Clin Lung Cancer. 2017; 18:198–206. https://doi.org/10.1016/j.clc.2016.07.001 PMID: 27495385

26. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012; 7:e51862. https://doi.org/10.1371/journal.pone.0051862 PMID: 23251644

27. Groheux D, Giacchetti S, Moretti J-L, Porcher R, Espie M, Lehmann-Che J, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. European journal of nuclear medicine and molecular imaging. 2011; 38:426–35. https://doi.org/10.1007/s00259-010-1640-9 PMID: 21057787

28. Wu J, Li B, Sun X, Cao G, Rubin DL, Napel S, et al. Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. Radiology. 2017; 286:401–13. https://doi.org/10.1148/radiol.2017162823 PMID: 28708462

29. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The Lancet. 2001; 357:539–45.

30. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. 2002; 72:621–7.

31. Kalkanis A, Kalkanis D, Drougas D, Vavougios GD, Datseris I, Judson MA, et al. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis. Nuclear Medicine Communications. 2016; 37:273–7. PMID: 26644095
32. Emami H, Singh P, MacNabb M, Vucic E, Lavender Z, Rudd JH, et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiосplenic axis in humans. JACC: Cardiovascular Imaging. 2015; 8:121–30. https://doi.org/10.1016/j.jcmg.2014.10.009 PMID: 25577441

33. Kim EJ, Kim S, Seo HS, Kang DO. The metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18F-FDG PET imaging. Circulation: Cardiovascular Imaging. 2014:CIRCIMAGING. 113.001093.

34. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014; 25:1901–14. https://doi.org/10.1093/annonc/mdu042 PMID: 24769692

35. van Kruijsdijk RCM, van der Wall E, Visseren FLJ. Obesity and Cancer: The Role of Dysfunctional Adipose Tissue. Cancer Epidemiology Biomarkers & Prevention. 2009; 18: 2569–78.

36. Abikhzer G, Alabed YZ, Azoulay L, Assayag J, Rush C. Altered Hepatic Metabolic Activity in Patients With Hepatic Steatosis on FDG PET/CT. American Journal of Roentgenology. 2011; 196:176–80. https://doi.org/10.2214/AJR.10.4679 PMID: 21178064

37. Kubota K, Watanabe H, Murata Y, Yukihiro M, Ito K, Morooka M, et al. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nuclear Medicine and Biology. 38:347–51. https://doi.org/10.1016/j.nucmedbio.2010.09.004 PMID: 21492783

38. Lin C-Y, Lin W-Y, Lin C-C, Shih C-M, Jeng L-B, Kao C-H. The negative impact of fatty liver on maximum standard uptake value of liver on FDG PET. Clinical Imaging. 35:437–41. https://doi.org/10.1016/j.clinimag.2011.02.005 PMID: 22040787

39. Pak K, Kim S-J, Kim IJ, Kim K, Kim H, Kim SJ. Hepatic FDG Uptake is not Associated with Hepatic Steatosis but with Visceral Fat Volume in Cancer Screening. Nuclear Medicine and Molecular Imaging. 2012; 46:176–81. https://doi.org/10.1007/s13139-012-0143-y PMID: 24900057